Pharmafile Logo

Fighting talk

April 2, 2015 | Cancer 

One thing that grasps my interest is how society has adopted military style language when talking about cancer

Treatments are described as “defending” or “protecting” whilst cancer patients themselves are “fighters” who “battle” to “beat” the disease. These abstract metaphors of war are used in an attempt to articulate that cancer is a very emotional experience for all involved.

This terminology is intriguing to me, as whilst widely recognised as persuasive, it is also considered controversial.  War-like analogies suggest that there will be a “winner”, “loser”, and a “battlefield”. Sadly there are hundreds of types of cancer, and short of resection, there is no definitive cure for any of them. Many patients inevitably end up the “loser” as they endure a “battle” against symptoms of the disease, and the side effects of therapy – which all too often only gains a few more months PFS before the “fight” is “lost”. Perhaps more poignantly, their own bodies are the “battlefield” where this all takes place. I have to ask myself, how do progressed metastatic patients feel anything other than failure when we talk about the disease in this way? 
When I’ve personally conducted interviews with medical professionals and patients alike, I hear time and time again their aversion to this style of language. Oncologists have even told me that in medical school they were taught to actively avoid using this vocabulary, and as a result they are unresponsive to any type of marketing materials delivered in this style.

So why, when companies are spending so much time and resources into researching effective messaging, are we continuing to use language that knowingly disengages the target audience? As researchers we know that it’s imperative to ensure that brand messaging speaks directly, and appropriately, to our target audience – and sometimes when conducting research that’s not always just about what the respondent says but rather, how they say it. By including some extra language profiling questions and completing an extra step of analysis when conducting market research, we can determine what segments are likely to exhibit a particular trend of language compared to another segment. The value to this insight is that our language is usually indicative of our behaviour; thus providing an extra layer of understanding into the minds of customers in terms of how they might behave in a particular context, which can inform both communications and sales materials.

Knowing what language ‘works’ for different customers can bring to life the other key factors that are relevant to each audience segment – which not only increases buy-in at implementation but also tailors the communication for optimal outcomes.

With approximately 100 projects conducted in oncology within the last 2 years, it’s the single largest therapeutic area studied at the Research Partnership, and it is clear to see that advances in detecting, diagnosing, and treating cancer have evolved – and are continuing to evolve at a significant rate. Perhaps it’s time we also evolve the way we talk about it, ensuring that we speak in language relevant to the target audience, avoid the “fighting talk” clichés and start using unique positive terminology to talk about “life beyond cancer”?

Research Partnership is one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical industry, we use our expertise and experience to deliver intelligent, tailor-made solutions. We provide strategic recommendations that go beyond research, helping our clients to answer their fundamental business challenges.Find out more here: http://bit.ly/1IxUzjW

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Video: Conducting mobile conference research

Our digital expert, Director John Branston explores how a mobile approach offers a better way of evaluating the impact of your conference presence

Free Thinking: From promise to practice: immuno-oncology in action

Our latest Free Thinking white paper series explores what the global outlook is like for new immunotherapy products and asks key opinion leaders and payers how they’re faring both clinically...

Video: Syndicated patient record data

Track the global market in real time

Video: Patient level prescribing decisions

Quantitative Director Duncan Munro explores the benefits of using patient level prescribing decisions.There is no “one size fits all” approach to conducting demand assessments. The best studies utilise a methodology...

Pharma Market Research Report – Predictions for 2016

PMR invited US President Harriet Kozak to submit her predictions for 2016

Pharmaceutical Market Research Conference 2016

Research Partnership exhibited and presented a paper at the Pharmaceutical Market Research Conference last week in Parsippany, NJ.Representing Research Partnership were US President Harriet Kozak and Director Phil Rosenberg.Harriet presented the paper...

Nicole Bender Moreira promoted to Associate Director, Singapore office

Research Partnership is delighted to announce the promotion of Nicole Bender Moreira to Associate Director in recognition of the contribution she has made to the growing success of our Singapore...

New appointments announced across Research Partnership’s global offices

We are delighted to welcome Marianne Jaeger as Associate Director to our London headquarters

What to Consider When Conducting Patient Research in Saudi Arabia

The need to understand the patient as a key stakeholder is now recognized by pharma across the globe.

Research Partnership hires Graphic Designer to create storytelling deliverables

Research Partnership has extended its healthcare research and consulting offering to include storytelling deliverables with the hire of multi-media graphic designer Amanda Brent at the company’s London headquarters. Working with...